Compounding Pharmacy GLP-1 | Red Byrd Consulting

Semaglutide and Trizepatide

Compounded Pharmacy GLP-1's, Specialty Peptides and B12 Shots

At Red Byrd Consulting Corp., we are committed to enhancing patient care by collaborating with industry leaders. Our partnership with multiple Compounding Pharmacies allows us to offer healthcare professionals access to customized GLP-1 receptor agonist medications, specialty peptides, and B12 injections.

Why Partner with Red Byrd?

Quick Turnaround: Efficient preparation and delivery of compounded medications to meet your patients' needs promptly.

Licensed Sterile Compounding: Adherence to stringent regulatory guidelines ensures the highest standards of pharmacy practice.

FDA-Registered Suppliers: Utilization of ingredients from FDA-registered suppliers guarantees safety and efficacy.

Customized Solutions: Tailored compounded medications designed to align with individual patient treatment plans.

Enhancing Patient Care Together:

Our collaborative partnerships empowers healthcare providers to deliver personalized medication solutions, supporting patients in achieving their health and wellness goals.

Not Just for Weight Loss Anymore:

Recent research indicates that GLP-1 receptor agonists, particularly semaglutide, extend beyond their initial applications in diabetes and weight management to show promise in treating addictive disorders. A randomized clinical trial published in JAMA Psychiatry involved 48 adults with alcohol use disorder receiving weekly Semaglutide injections. Results demonstrated a significant reduction in alcohol consumption and cravings among participants compared to a placebo group. Additionally, preclinical studies have found that Semaglutide reduces alcohol intake in rodent models, supporting its potential in addiction treatment. These findings suggest that Semaglutide may influence the brain's reward pathways associated with addictive behaviors, warranting further investigation into its efficacy across various substance use disorders.

Please see the preclinical studies below. We are happy to provide them if requested.

For more information on how this partnership can benefit your practice and patients, please reach out to us:

Phone: (828) 476-1295
Email: info@redbyrdconsulting.com
Website: www.redbyrdconsulting.com

Important FDA Notice:

The FDA has expressed concerns regarding unapproved GLP-1 drugs marketed for weight loss. All compounded medications comply with FDA regulations and are sourced from FDA-registered suppliers to ensure safety and efficacy.

< Back